Korro Bio (Nasdaq: KRRO) announced an inducement grant under Nasdaq Listing Rule 5635(c)(4) for a newly hired employee.
Korro granted a nonstatutory stock option to purchase 15,000 shares at an exercise price of $13.46 per share (closing price on April 8, 2026). The option has a 10-year term and vests over four years (25% at year one, then monthly over 36 months). The grant was approved by a majority of independent directors under Korro's 2026 Inducement Plan and was made as an inducement to hire in accordance with Nasdaq rule 5635(c)(4).
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – KRRO
+7.97%
+7.97%Session close to close
In the Apr 13 session, KRRO gained 7.97%, reflecting a notable positive market reaction.
The stock moved +8.0% in the session following this news. A strong positive reaction aligns with the...
Analysis
The stock moved +8.0% in the session following this news. A strong positive reaction aligns with the stock’s tendency to respond sharply to corporate developments, even when the announcement itself is administrative, such as an inducement option grant under Nasdaq Listing Rule 5635(c)(4). Investors have recently focused on financing strength and insider participation, alongside an effective S-3 shelf covering 7,650,764 shares for resale, which could influence how continued news flow affects sentiment.
Key Figures
Option grant size:15,000 sharesExercise price:$13.46 per shareOption term:10 years+3 more
6 metrics
Option grant size15,000 sharesNon-statutory stock option to new employee
Exercise price$13.46 per shareSet at Nasdaq closing price on April 8, 2026
Option term10 yearsMaximum life of inducement option
Initial vesting tranche25% after 1 yearVests on first anniversary of start date
Remaining vesting75% over 36 monthsEqual monthly installments to fourth anniversary
Grant effective date price$13.46Closing price on April 8, 2026 used for option strike
J.P. Morgan conference presentation notice aligned with a notable gain.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent clearly positive financing and earnings updates saw double‑digit gains, while conference and event announcements produced more mixed, sometimes contrarian, price reactions.
Recent Company History
Over the last few months, Korro combined corporate events with significant financing and pipeline milestones. An $85M oversubscribed private placement and full‑year 2025 results both coincided with double‑digit gains. Earlier conference and analyst day announcements around KRRO-121 and GalNAc AATD programs produced smaller, mixed moves. Today’s Nasdaq Rule 5635(c)(4) inducement option grant fits the pattern of routine corporate updates with limited fundamental impact compared with prior financing catalysts.
Key Terms
non-statutory stock option, exercise price, vesting, inducement plan, +1 more
5 terms
non-statutory stock optionfinancial
"announced the grant of a non-statutory stock option to one newly hired employee"
A non-statutory stock option is a company-granted right that lets a person buy shares later at a set price but does not receive special tax-favored treatment under tax law. It matters to investors because when the option is used the holder usually pays ordinary income tax on the gain and the company records compensation cost and issues new shares, which can reduce existing owners’ percentage ownership—think of it like a coupon to buy stock that creates a taxable event and some dilution.
exercise pricefinancial
"a nonstatutory stock option to purchase 15,000 shares ... at an exercise price of $13.46 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vestingfinancial
"The option has a ten-year term and vests over four years, with 25% of the shares vesting"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
inducement planfinancial
"approved ... pursuant to Koro’s 2026 Inducement Plan and was made as an inducement material"
An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.
nasdaq listing rule 5635(c)(4)regulatory
"inducement material to the employee’s acceptance of employment ... in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
CAMBRIDGE, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced the grant of a non-statutory stock option to one newly hired employee.
Korro granted the new employee a nonstatutory stock option to purchase 15,000 shares of Korro’s common stock at an exercise price of $13.46 per share, the closing price per share of Korro's common stock as reported by Nasdaq on the grant effective date, April 8, 2026. The option has a ten-year term and vests over four years, with 25% of the shares vesting on the first anniversary of the employee’s start date and the remaining 75% vesting in 36 equal monthly installments on each monthly anniversary thereafter until the fourth anniversary of the employee’s start date, subject to the employee’s continued service with Korro through each applicable vesting date.
This grant was approved by a majority of the independent directors of Korro’s board of directors pursuant to Koro’s 2026 Inducement Plan and was made as an inducement material to the employee’s acceptance of employment with Korro in accordance with Nasdaq Listing Rule 5635(c)(4).
About Korro
Korro is a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, enabling a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com
Korro Bio Contact Information
Investor & Media Contact Malini Chatterjee, Ph.D Blueprint Life Science Group mchatterjee@bplifescience.com or ir@korrobio.com 917.330.4269
FAQ
What did Korro Bio (KRRO) grant to its new hire on April 8, 2026?
Korro granted a nonstatutory stock option to purchase 15,000 shares at $13.46 per share. According to Korro, the option carries a ten-year term and vests over four years with 25% at the first anniversary and monthly vesting thereafter.
How does the vesting schedule for the KRRO inducement option work?
The option vests 25% on the first anniversary and the remaining 75% monthly over 36 months. According to Korro, vesting is subject to the employee's continued service through each applicable vesting date under the inducement grant.
Why did Korro Bio use Nasdaq Listing Rule 5635(c)(4) for the KRRO grant?
Korro used Nasdaq Listing Rule 5635(c)(4) to classify the award as an inducement material to hire the employee. According to Korro, the grant was approved by a majority of independent directors under its 2026 Inducement Plan.
What is the exercise price and effective grant date for the KRRO option?
The exercise price is $13.46 per share, equal to the closing price on the grant effective date, April 8, 2026. According to Korro, the price was set based on Nasdaq's reported closing price that day for common stock.
How long does the KRRO stock option remain exercisable after the grant?
The option has a ten-year term from the grant effective date, during which it may be exercised. According to Korro, the full ten-year exercise period applies subject to the option's vesting schedule and continued service conditions.
Who approved the Korro (KRRO) inducement grant under the 2026 Inducement Plan?
A majority of Korro's independent directors approved the inducement grant under the 2026 Inducement Plan. According to Korro, this approval satisfied Nasdaq Listing Rule 5635(c)(4) requirements for inducement awards to new employees.
